Showing results (111-120 of 148) with videos related to
Sort By:
Pageof 15
Proceedings of the National Academy of Sciences of the United States of America|April 15, 1993
Transcription factor E2F binds DNA as a heterodimerH E Huber, G Edwards, P J Goodhart, et al.Journal of Medicinal Chemistry|July 1, 1991
Gastrin releasing peptide antagonists with improved potency and stabilityD C Heimbrook, W S Saari, N L Balishin, et al.The Journal of Biological Chemistry|February 4, 1994
cDNA cloning and expression of rat and human protein geranylgeranyltransferase type-IF L Zhang, R E Diehl, N E Kohl, et al.Investigational New Drugs|April 1, 1992
Activity of a recombinant transforming growth factor-alpha-Pseudomonas exotoxin hybrid protein against primary human tumor colony-forming unitsD D Von Hoff, M H Marshall, D C Heimbrook, et al.Molecular and Cellular Biology|February 1, 1993
Protein domains governing interactions between E2F, the retinoblastoma gene product, and human papillomavirus type 16 E7 proteinP S Huang, D R Patrick, G Edwards, et al.Oncogene|November 1, 1993
Characterization of the retinoblastoma binding proteins RBP1 and RBP2A R Fattaey, K Helin, M S Dembski, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|February 22, 2001
PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolitesB K Wong, D DeFeo-Jones, R E Jones, et al.Proceedings of the National Academy of Sciences of the United States of America|February 1, 1986
Mutant ras-encoded proteins with altered nucleotide binding exert dominant biological effectsI S Sigal, J B Gibbs, J S D'Alonzo, et al.Molecular and Cellular Biology|August 1, 1991
Identification of amino acid residues required for Ras p21 target activationM S Marshall, L J Davis, R D Keys, et al.Anti-Cancer Drug Design|October 1, 1987
Molecular approaches towards an anti-ras drugI S Sigal, G M Smith, F Jurnak, et al.Pageof 15